| pubmed-article:16415533 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16415533 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:16415533 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:16415533 | lifeskim:mentions | umls-concept:C0021493 | lld:lifeskim |
| pubmed-article:16415533 | lifeskim:mentions | umls-concept:C0016277 | lld:lifeskim |
| pubmed-article:16415533 | lifeskim:mentions | umls-concept:C0031139 | lld:lifeskim |
| pubmed-article:16415533 | lifeskim:mentions | umls-concept:C1452382 | lld:lifeskim |
| pubmed-article:16415533 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:16415533 | pubmed:dateCreated | 2006-1-17 | lld:pubmed |
| pubmed-article:16415533 | pubmed:abstractText | Fluconazole (FLCZ) is an antifungal agent that is efficacious in the treatment of fungal peritonitis. Fosfluconazole (F-FLCZ) is the phosphate prodrug of FLCZ, which is highly soluble compared with FLCZ. F-FLCZ is useful against fungal peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients because it has a high water solubility. The aims of the present study were to characterize the peritoneal permeability of FLCZ and the pharmacokinetics of FLCZ and F-FLCZ after intraperitoneal (i.p.) administration to peritoneal dialysis rats. FLCZ or F-FLCZ was administered intravenously and intraperitoneally. After the i.p. administration of F-FLCZ, FLCZ was detected in circulating blood and the dialyzing fluid in peritoneal dialysis rats. The concentration of plasma FLCZ after the i.p. F-FLCZ administration was lower than that after the intravenous (i.v.) F-FLCZ administration. It is considered that the dose should be increased appropriately when F-FLCZ is administered intraperitoneally. The profiles of plasma FLCZ after i.v. and i.p. administrations were analyzed using a two-compartment model in which the distribution volume of the peripheral compartment was fixed at a volume of the dialyzing fluid (peritoneal dialysis PK model). The peritoneal dialysis PK model could describe the profiles of plasma and dialyzing fluid FLCZ. These results suggest that FLCZ and F-FLCZ could be administered intraperitoneally for the treatment of fungal peritonitis in CAPD patients. | lld:pubmed |
| pubmed-article:16415533 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16415533 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16415533 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16415533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16415533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16415533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16415533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16415533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16415533 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16415533 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:16415533 | pubmed:issn | 1347-4367 | lld:pubmed |
| pubmed-article:16415533 | pubmed:author | pubmed-author:MatsumotoYosh... | lld:pubmed |
| pubmed-article:16415533 | pubmed:author | pubmed-author:OgataKazuhiro... | lld:pubmed |
| pubmed-article:16415533 | pubmed:author | pubmed-author:AoyamaTakahik... | lld:pubmed |
| pubmed-article:16415533 | pubmed:author | pubmed-author:ShimizuMakiko... | lld:pubmed |
| pubmed-article:16415533 | pubmed:author | pubmed-author:ShimaYoshinor... | lld:pubmed |
| pubmed-article:16415533 | pubmed:author | pubmed-author:HattaShigeoS | lld:pubmed |
| pubmed-article:16415533 | pubmed:author | pubmed-author:KimuraKenjiro... | lld:pubmed |
| pubmed-article:16415533 | pubmed:author | pubmed-author:MasuharaKeiso... | lld:pubmed |
| pubmed-article:16415533 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16415533 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:16415533 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16415533 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16415533 | pubmed:pagination | 485-90 | lld:pubmed |
| pubmed-article:16415533 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:meshHeading | pubmed-meshheading:16415533... | lld:pubmed |
| pubmed-article:16415533 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16415533 | pubmed:articleTitle | Pharmacokinetics of fluconazole and fosfluconazole after intraperitoneal administration to peritoneal dialysis rats. | lld:pubmed |
| pubmed-article:16415533 | pubmed:affiliation | Department of Clinical Pharmacology and Toxicology, Showa Pharmaceutical University, Tokyo, Japan. | lld:pubmed |
| pubmed-article:16415533 | pubmed:publicationType | Journal Article | lld:pubmed |
